MIRUM PHARMACEUTICALS Reports Fourth Quarter FY2022 Earnings Results for December 31, 2022
March 19, 2023
Earnings Overview
On March 8 2023, MIRUM PHARMACEUTICALS ($BER:08D) released their financial results for the fourth quarter of FY2022, ending on December 31 2022. Year-on-year, total revenue had decreased by 163.3%, from USD -36.4 million. However, net income had increased by 788.9%, to USD 27.9 million.
Stock Price
On Wednesday, MIRUM PHARMACEUTICALS reported its fourth quarter FY2022 earnings results for December 31, 2022. The stock opened at €22.4 and closed at the same price, down by 0.9% from the previous closing price of €22.6. Despite the slight decline, investors remain optimistic as the company showed a strong performance throughout the year. The company also showed an increase in net income, with an increase of 8% compared to the same period last year. This was mainly due to the company’s continued focus on cost control and efficient management. MIRUM PHARMACEUTICALS also saw improvement in its product portfolio, as it launched several new drugs as well as gaining approval for existing drugs in new markets.
Furthermore, the company has continued to make investments in research and development, which led to additional drug approvals. These efforts have been a major contributor to the company’s success in recent years. Overall, the report from MIRUM PHARMACEUTICALS showed a positive performance for the fourth quarter of FY2022 and investors remain optimistic about future results. The company’s dedication to cost control and product innovation has put them in a strong position to capitalize on growth opportunities in the upcoming year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Mirum Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 77.06 | -135.66 | -177.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Mirum Pharmaceuticals. More…
| Operations | Investing | Financing |
| -120.14 | 7.7 | 109.09 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Mirum Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 352.91 | 210.87 | 3.84 |
Key Ratios Snapshot
Some of the financial key ratios for Mirum Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -163.6% |
| FCF Margin | ROE | ROA |
| -156.3% | -50.6% | -22.3% |
Analysis
At GoodWhale, we evaluate the fundamentals of MIRUM PHARMACEUTICALS with great detail and precision. Our Star Chart gives MIRUM PHARMACEUTICALS an intermediate health score of 4/10, which means that the company has a solid enough financial state to safely ride out any crisis without the risk of bankruptcy. MIRUM PHARMACEUTICALS is classified as a “cheetah” – a type of company that achieves high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who are interested in MIRUM PHARMACEUTICALS should have an eye for growth, as this company is strong in that area. While the company is medium in asset strength and weak in dividend and profitability, they are still able to achieve high revenue and earnings growth. As such, investors looking for long term growth potential could be interested in investing in MIRUM PHARMACEUTICALS. More…
Summary
MIRUM PHARMACEUTICALS reported their fourth quarter earnings for FY2022, with total revenue of USD -36.4 million, and net income of USD 27.9 million. Despite the decline in total revenue, the company experienced a strong increase in net income, which grew by 788.9%. Investors looking at MIRUM PHARMACEUTICALS should consider this overall positive performance, despite a decrease in total revenue. This could be an indication that the company is doing well financially in the long run as well as making positive changes to its operations.
